PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PTC THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$61.53+2.29 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
PTC THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $238.82M | $225.57M | $183.99M | $130.96M | $118.33M | $153.43M | $135.90M | $135.42M | $133.22M | $177.60M | $131.99M | $144.04M | 66.2% | +101.8% |
| Sephience | $151.31M | $124.55M | $91.59M | $19.56M | – | – | – | – | – | – | – | – | 42.0% | – |
| Royalty revenue | $71.11M | $46.84M | $79.39M | $70.79M | $57.61M | $36.44M | $58.16M | $61.37M | $53.18M | $31.15M | $51.00M | $50.17M | 19.7% | +23.4% |
| Collaboration and license revenue | $50.60M | $143.00K | – | $9.26M | $2.94M | $986.23M | – | – | – | – | – | – | 14.0% | +1620.3% |
| Translarna | $42.22M | $58.98M | – | $50.67M | $59.47M | $86.15M | – | $72.28M | $70.35M | – | – | – | 11.7% | -29.0% |
| Emflaza | $24.63M | $21.48M | $27.06M | $35.16M | $36.35M | $47.79M | $50.50M | $51.94M | $47.30M | – | – | – | 6.8% | -32.2% |
| Upstaza/Kebilidi | $11.16M | $9.59M | – | – | $11.89M | $8.66M | – | – | – | – | – | – | 3.1% | -6.1% |
| All other products | $9.50M | $10.97M | $5.99M | $9.83M | $10.62M | $10.82M | $3.28M | $11.20M | $13.99M | – | – | – | 2.6% | -10.6% |
| Manufacturing revenue | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $301.00K | $1.36M | $971.00K | $2.37M | – | – |
| Collaboration revenue | – | – | – | – | – | – | – | – | – | – | $100.02M | $0 | – | – |
| Upstaza | – | – | – | $15.74M | $11.89M | – | – | – | $1.59M | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $152.18M | $136.52M | $111.62M | $56.42M | $36.35M | $47.79M | $50.50M | $51.94M | $47.30M | – | – | – | 42.2% | +318.6% |
| All other countries | $52.84M | $44.60M | $47.69M | $40.20M | $22.90M | $57.62M | $31.97M | $53.30M | $53.40M | – | – | – | 14.7% | +130.7% |
| Brazil | $25.58M | $41.21M | $5.98M | $9.22M | $18.12M | $9.51M | $3.78M | $29.22M | $30.38M | – | – | – | 7.1% | +41.1% |
| Russia | $8.21M | $3.25M | $18.70M | $25.11M | $40.95M | $38.51M | $49.66M | $965.00K | $2.15M | – | – | – | 2.3% | -80.0% |
From the segment and revenue-disaggregation notes of Ptc Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.